



FINANCIAL TEAR SHEET

CORPORATE PROFILE

The mission of CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. In addition to our fully-owned programs, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Basel, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.

PRIMARY IR CONTACT


Chris Brinzey
Westwicke Partners
Phone: 339-970-2843
E-mail:
chris.brinzey@westwicke.com

STOCK PERFORMANCE

CRSP (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$17.74
Change (%)	▲ 0.25 (1.43%)
Volume	96,305
52 Week Low	\$11.63
Market Cap	\$699,556,712
Rolling EPS	-1.89
PE Ratio	0
Shares Outstanding	39,997,525

Data as of 07/26/17 4:00 p.m. ET



RECENT HEADLINES & EVENTS

Jul-25-2017 - 5:01 p.m.
CRISPR Therapeutics, Intellia Therapeutics,
Caribou Biosciences and ERS Genomics
Announce Appellate Brief Seeking Reversal of
U.S. Patent Board Decision on CRISPR/Cas9
Gene Editing

Jul-10-2017 - 8:30 a.m.
CRISPR Therapeutics and Neon Therapeutics
Enter Research Collaboration

Jul-05-2017 - 4:30 p.m.
CRISPR Therapeutics to Present at the Piper
Jaffray GenomeRx Symposium

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
07/25/17	8-K
07/25/17	8-K
07/17/17	4
07/13/17	4

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources